These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22383557)

  • 1. Protease inhibitors: silver bullets for chronic hepatitis C infection?
    Alkhouri N; Zein NN
    Cleve Clin J Med; 2012 Mar; 79(3):213-22. PubMed ID: 22383557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964
    [No Abstract]   [Full Text] [Related]  

  • 3. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M; Silva M; Spooner L; Comee MK; Malloy M
    Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
    Nelson DR
    Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
    Crespo G; Lens S
    Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
    Dusheiko G; Wedemeyer H
    Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C drug development at a crossroads.
    Nelson DR
    Hepatology; 2009 Oct; 50(4):997-9. PubMed ID: 19787813
    [No Abstract]   [Full Text] [Related]  

  • 12. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
    Pawlotsky JM
    Gastroenterology; 2011 Mar; 140(3):746-54. PubMed ID: 21255572
    [No Abstract]   [Full Text] [Related]  

  • 15. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
    Barritt AS; Fried MW
    Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease inhibitors for hepatitis C: economic implications.
    Turner SJ; Brown J; Paladino JA
    Pharmacoeconomics; 2013 Sep; 31(9):739-51. PubMed ID: 23839698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
    Bodeau S; Nguyen-Khac E; Solas C; Bennis Y; Capron D; Duverlie G; Brochot E
    J Clin Pharmacol; 2015 May; 55(5):517-24. PubMed ID: 25535910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
    ; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
    Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.